Protective effect of Astragalus Angelica ointment on autogenous arteriovenous fistula in patients with maintenance hemodialysis

doi:10.3877/cma.j.issn.2095-3216.2023.02.005

Abstract

Abstract:

Objective

To investigate the effect of Astragalus Angelica ointment combined with individualized intervention on autologous arteriovenous fistula (AVF) in patients with maintenance hemodialysis (MHD).

Methods

MHD patients with AVF admitted from March 2019 to May 2021 were randomly divided into observation group (87 cases) and control group (89 cases). The control group was given individualized intervention, and the observation group was treated with Astragalus Angelica ointment combined with the individualized intervention for 2 weeks. The two groups were compared in vessel diameter, anastomotic blood flow, AVF patency rate, serum levels of hypoxia-inducible factor-1α (HIF-1α), platelet-derived growth factor (PDGF) and vascular endothelial growth factor (VEGF), as well as AVF complications.

Results

After treatment, the blood vessel diameter and anastomotic blood flow of both groups were increased, especially in the observation group (P<0.05). The patency rate of AVF of the observation group was higher than that of the control group (P<0.05). After treatment, the serum levels of HIF-1α, VEGF and PDGF in the observation group were also significantly increased (P<0.05). The AVF complication rate of the observation group (6.90%) was apparently lower than that of the control group (25.84%) (P<0.05).

Conclusion

The Astragalus Angelica ointment may have an effect in improving the AVF blood flow and reducing the AVF complications in the MHD patients.

Key words: Maintenance hemodialysis, Autologous arteriovenous fistula, Astragalus Angelica ointment, Protective effect

Jun Li, Li Lin, Jianmei Wang, Fen Li, Lili Liu, Xingyu Wang, Jie Ding. Protective effect of Astragalus Angelica ointment on autogenous arteriovenous fistula in patients with maintenance hemodialysis[J]. Chinese Journal of Kidney Disease Investigation(Electronic Edition), 2023, 12(02): 87-92.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhsbyjdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-3216.2023.02.005

https://zhsbyjdzzz.cma-cmc.com.cn/EN/Y2023/V12/I02/87

Figures/Tables 5

References 31

[1]	马鹏跃，吴永东，黄凤璋，等. 血液透析患者动静脉内瘘晚期失功影响因素及其预测效能[J]. 山东医药，2021 ，61(12): 81-84.
[2]	陈沁兰. 滋养血管在自体动静脉内瘘静脉内膜增生中的作用[J]. 肾脏病与透析肾移植杂志，2022, 31(1): 90-94.
[3]	黄巳悦，王惠明. 人工血管动静脉内瘘单中心应用效果观察[J]. 中国医药，2022, 17(4): 563-567.
[4]	王文越，刘珊，吕琴，等. 黄芪-当归药对益气活血药理作用研究进展[J]. 中国实验方剂学杂志，2021, 27(6): 207-216.
[5]	汪兴玲，童钟，王海燕，等. 个体化分阶段心理干预在肝癌患者围手术期中的应用[J]. 中国实用护理杂志，2021, 37(13): 1003-1008.
[6]	杨月香，杨玉，温卿，等. 水胶体敷料在动静脉内瘘扣眼祛痂患者中的应用[J]. 齐鲁护理杂志，2017, 23(11): 113-114.
[7]	徐曼，周琼荣，谭莲，等. 水胶体敷料联合湿热敷对动静脉内瘘穿刺后血肿的影响[J]. 中国医药导报，2020, 17(16): 90-93.
[8]	刘辉，邵福波，宫响. 经典相关系数及统计功效对比研究[J]. 青岛科技大学学报(自然科学版), 2022, 43(1): 111-119.
[9]	中国医院协会血液净化中心分会血管通路工作组. 中国血液透析用血管通路专家共识(第2版)[J]. 中国血液净化，2019, 18(6): 365-381.
[10]	王培莉，施素华，林巧红，等. 治疗性沟通系统改善维持性血液透析病人负性情绪的研究进展[J]. 护理研究，2020, 34(9): 1561-1565.
[11]	晏子友，胡良伟，沈金峰，等. 肾衰方对维持性血液透析的临床疗效分析[J]. 中华中医药学刊，2021, 39(6): 14-17.
[12]	林燕娜，冯志瑀，黎志彬，等. 慢性肾衰竭维持性血液透析合并不宁腿综合征的中医证候研究[J]. 广州中医药大学学报，2018, 35(3): 383-387.
[13]	莫雅文，黄静雅，孙春艳，等. 维持性血液透析病人自体动静脉内瘘功能的评价与干预现状[J]. 护理研究，2020, 34(1): 119-122.
[14]	苏姗娜，何达. 风险分级护理对维持性血液透析病人动静脉内瘘功能的影响[J]. 护理研究，2019, 33(19): 3445-3447.
[15]	Tao YG, Huang XF, Wang JY, et al. Exploring molecular mechanism of huangqi in treating heart failure using network pharmacology [J]. Evid Based Complement Alternat Med, 2020, 2020: 6473745.
[16]	Bao YR, Jiang WY, Yu JY, et al. Traditional Chinese medicine formulation Huangqi Jianzhong Tang improves cardiac function after myocardial infarction in rats [J]. Evid Based Complement Alternat Med, 2020, 2020: 3106076.
[17]	Xu C, Wang Y, Feng J, et al. Extracts from Huangqi and Ezhu inhibit Lewis lung carcinoma cell growth in a xenograft mouse model by impairing mitogen-activated protein kinase signaling, vascular endothelial growth factor production, and angiogenesis [J]. J Tradit Chin Med, 2019, 39(4): 559-565.
[18]	张丽，高怡，栗江霞，等. 黄芪外用对慢性伤口护理效果影响的系统评价[J]. 护理研究，2022, 36(13): 2414-2419.
[19]	李俊梅. 自拟黄芪红花膏外用治疗感染性创面50例[J]. 中国药业，2014(12): 108-108, 109.
[20]	徐昊，黄小平，张伟，等. 黄芪和当归的主要活性成分配伍对骨髓抑制小鼠造血功能的影响[J]. 中国药理学通报，2019, 35(5): 707-713.
[21]	Shi XQ, Yue SJ, Tang YP, et al. A network pharmacology approach to investigate the blood enriching mechanism of Danggui Buxue decoction [J]. J Ethnopharmacol, 2019, 23(5): 227-242.
[22]	滕敬华，马丽，王俊杰. 当归和白及外用联合雾化吹氧法治疗Ⅲ期压疮的研究[J]. 检验医学与临床，2014(10): 1384-1385.
[23]	王俊杰，李伏燕，李薇，等. 当归白及外用联合特定电磁波治疗器防治Ⅰ期压疮的临床研究[J]. 检验医学与临床，2014(9): 1217-1218.
[24]	董蕊，王盼，逯影. 炙甘草和当归黄酮类成分配伍治疗烫伤的剂型初步研究[J]. 中国中药杂志，2021, 46(22): 5810-5818.
[25]	马慧淼，陈媚，杨嘉欣，等. 基于数据挖掘探索中药外用治疗手足综合征的用药规律[J]. 湖南中医药大学学报，2019, 39(9): 1120-1124.
[26]	魏巧兰，邱静，栾云，等. 中药贴敷配合温和灸促进血液透析患者动静脉内瘘成熟研究[J]. 护理学杂志，2018, 33(3): 54-56.
[27]	姚卫国，杨美霞，刘琨. 中药护瘘贴改善尿毒症患者动静脉内瘘功能的临床疗效[J]. 上海医药，2022, 43(1): 28-30, 46.
[28]	黄志霞，李桂珍，钟慧. 四黄水蜜膏联合喜疗妥治疗动静脉内瘘皮下血肿疗效观察[J]. 护理实践与研究，2018, 15(2): 30-32.
[29]	Yin Y, Li H, Chen Y, et al. Combination of Astragalus membranaceous and Angelica sinensis ameliorates vascular endothelial cell dysfunction by inhibiting oxidative stress [J]. Evid Based Complement Alternat Med, 2020, 2020: 6031782.
[30]	邱乐乐，程艳爽，王建荣，等. 多磺酸粘多糖乳膏不同用药时机对自体动静脉内瘘穿刺并发症的疗效观察[J]. 中华保健医学杂志，2020, 22(5): 519-521.
[31]	Shi XQ, Zhu ZH, Yue SJ, et al. Integration of organ metabolomics and proteomics in exploring the blood enriching mechanism of Danggui Buxue decoction in hemorrhagic anemia rats [J]. J Ethnopharmacol, 2020, 26(1): 11-30.

项目	观察组(n＝87)	对照组(n＝89)	t/χ²值	P值
性别(男/女)	38/49	38/51	0.092	0.761
平均年龄(岁)	48.68±3.43	49.05±3.49	0.746	0.457
平均病程(年)	4.42±1.03	4.56±1.05	0.939	0.348
体重指数(kg/m²)	22.75±3.42	22.34±3.23	0.856	0.392
糖尿病肾病[例(%)]	29(33.33)	25(28.09)	0.789	0.673
高血压肾病[例(%)]	28(32.18)	29(32.58)	0.789	0.673
慢性肾炎肾病[例(%)]	30(34.48)	35(39.33)	0.789	0.673
低血压[例(%)]	55(63.22)	53(59.55)	0.329	0.566
居住地(城镇/农村)	53/34	55/34	0.172	0.677
吸烟[例(%)]	53(60.92)	58(65.17)	0.406	0.523
饮酒[例(%)]	48(55.17)	52(58.43)	0.213	0.643

项目	观察组(n＝87)	对照组(n＝89)	t/χ²值	P值
性别(男/女)	38/49	38/51	0.092	0.761
平均年龄(岁)	48.68±3.43	49.05±3.49	0.746	0.457
平均病程(年)	4.42±1.03	4.56±1.05	0.939	0.348
体重指数(kg/m²)	22.75±3.42	22.34±3.23	0.856	0.392
糖尿病肾病[例(%)]	29(33.33)	25(28.09)	0.789	0.673
高血压肾病[例(%)]	28(32.18)	29(32.58)	0.789	0.673
慢性肾炎肾病[例(%)]	30(34.48)	35(39.33)	0.789	0.673
低血压[例(%)]	55(63.22)	53(59.55)	0.329	0.566
居住地(城镇/农村)	53/34	55/34	0.172	0.677
吸烟[例(%)]	53(60.92)	58(65.17)	0.406	0.523
饮酒[例(%)]	48(55.17)	52(58.43)	0.213	0.643

组别	焦虑自评量表		抑郁自评量表		自我照顾机构量表
组别	干预前	干预后	干预前	干预后	干预前	干预后
观察组(n＝87)	40.64±4.63	37.57±4.80^a	35.92±5.46	26.12±6.24^a	72.94±8.05	100.87±10.27^a
对照组(n＝89)	41.16±4.53	36.38±5.53^a	35.34±3.55	27.70±5.22^a	73.73±10.44	98.49±10.91^a
t值	0.753	1.523	0.837	1.824	0.561	1.489
P值	0.452	0.130	0.404	0.070	0.575	0.138

组别	焦虑自评量表		抑郁自评量表		自我照顾机构量表
组别	干预前	干预后	干预前	干预后	干预前	干预后
观察组(n＝87)	40.64±4.63	37.57±4.80^a	35.92±5.46	26.12±6.24^a	72.94±8.05	100.87±10.27^a
对照组(n＝89)	41.16±4.53	36.38±5.53^a	35.34±3.55	27.70±5.22^a	73.73±10.44	98.49±10.91^a
t值	0.753	1.523	0.837	1.824	0.561	1.489
P值	0.452	0.130	0.404	0.070	0.575	0.138

组别	血管直径(mm)		吻合口血流量(ml)		管路通畅率[例(%)]
组别	干预前	干预后	干预前	干预后	管路通畅率[例(%)]
观察组(n＝87)	3.57±1.11	5.64±1.56^a	662.63±182.27	846.61±167.12^a	77(88.50)
对照组(n＝89)	3.82±1.36	4.82±1.30^a	673.94±194.72	761.42±196.52^a	64(71.91)
t/χ²值	1.334	3.792	0.398	3.095	7.605
P值	0.184	<0.001	0.691	0.002	0.006

Please choose a citation manager

Content to export